Eribulin effective for earlier treatment of metastatic breast cancer
the ONA take:
According to a new study published in the Journal of Clinical Oncology, researchers have found eribulin is active and well tolerated as first-, second-, or third-line therapy in patients with metastatic breast cancer.
For the study, researchers sought to determine the activity of eribulin as an early treatment for metastatic breast cancer.
For the phase 3 study, researchers randomly assigned 1,099 women with metastatic breast cancer who had previously been treated with an anthracycline or a taxane to receive either capecitabine or eribulin as first-, second-, or third-line therapy for metastatic breast cancer.
Results showed that there was no statistical difference in overall survival between capecitabine and eribulin. In addition, a subset analysis found that eribulin may be especially active in those with triple negative metastatic breast cancer, a type of breast cancer that is particularly difficult to treat because it does not respond to hormonal therapy or HER2-targeted therapies.
The findings suggest that eribulin may have a role earlier in the course of the treatment of metastatic breast cancer.
Eribulin is active and well tolerated as first-, second-, or third-line therapy in patients with metastatic breast cancer.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Prolactin Expression May Indicate Better Prognosis for Patients With TNBC
- Caregiver Mastery Linked to Patient Survival in Glioblastoma
- Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma
- Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|